Boston University

The University of British Columbia

The Brigham and Women's Hospital, Inc.

Health Research, Inc.

Marc Elliott Lenburg

Avrum Spira

Joshua David Campbell

Jennifer E Beane-Ebel

Ana Brandusa Pavel

Jerome S Brody

James Cameron Hogg

Dimitri Petchkovski

Julie Erin Zeskind Gil

Katrina Steiling

Alejandro A Diaz

Elizabeth Jeanne Becker

Darryl Andrew Knight

Mary E Reid

Sarah Mazzilli

Anna Tassinari

Ke Xu

Ehab Billatos

The technology described herein is directed to methods and compositions for prognosis and treatment of respiratory disease, e.g., COPD.

Methods and compositions relating to lung function

The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.

Methods relating to lung cancer

Described herein are methods relating to the diagnosis, prognosis, and treatment of airway dysfunction, e.g., bronchiectasis by detecting gene expression in a sample obtained from a subject. Exemplary samples include a bronchial brushing, nasal brushing, sputum, or peripheral blood sample.

Methods and compositions relating to airway dysfunction

The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Methods related to bronchial premalignant lesion severity and progression

Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.

Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants.

Diagnostic for lung disorders using class prediction

The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.

Therapeutic agent for emphysema and COPD

Growing community of inventors

Brookline, MA, United States of America

Marc Elliott Lenburg